Journal article
Characterizing the course of suicidal ideation response to ketamine
Journal of affective disorders, Vol.241, pp.86-93
12/01/2018
DOI: 10.1016/j.jad.2018.07.077
PMCID: PMC6193483
PMID: 30099268
Abstract
•The glutamatergic modulator ketamine causes rapid changes in suicidal ideation (SI).•We modeled change in SI post-ketamine administration and found three sub-groups.•Subgroups of SI response were: non-responders, responders, and remitters.•Indicators of chronic suicide risk were associated with non-response to ketamine.•The findings illuminate the heterogeneity of SI response to ketamine.
: No pharmacological treatments exist for active suicidal ideation (SI), but the glutamatergic modulator ketamine elicits rapid changes in SI. We developed data-driven subgroups of SI trajectories after ketamine administration, then evaluated clinical, demographic, and neurobiological factors that might predict SI response to ketamine.
: Data were pooled from five clinical ketamine trials. Treatment-resistant inpatients (n = 128) with DSM-IV-TR-diagnosed major depressive disorder (MDD) or bipolar depression received one subanesthetic (0.5 mg/kg) ketamine infusion over 40 min. Composite SI variable scores were analyzed using growth mixture modeling to generate SI response classes, and class membership predictors were evaluated using multinomial logistic regressions. Putative predictors included demographic variables and various peripheral plasma markers.
: The best-fitting growth mixture model comprised three classes: Non-Responders (29%), Responders (44%), and Remitters (27%). For Responders and Remitters, maximal improvements were achieved by Day 1. Improvements in SI occurred independently of improvements in a composite Depressed Mood variable for Responders, and partially independently for Remitters. Indicators of chronic SI and self-injury were associated with belonging to the Non-Responder group. Higher levels of baseline plasma interleukin-5 (IL-5) were linked to Remitters rather than Responders.
: Subjects were not selected for active suicidal thoughts; findings only extend to Day 3; and plasma, rather than CSF, markers were used.
: The results underscore the heterogeneity of SI response to ketamine and its potential independence from changes in Depressed Mood. Individuals reporting symptoms suggesting a longstanding history of chronic SI were less likely to respond or remit post-ketamine.
Details
- Title: Subtitle
- Characterizing the course of suicidal ideation response to ketamine
- Creators
- Elizabeth D Ballard - Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Building 10, CRC Room 7-5341, 10 Center Drive, MSC 1282, Bethesda, MD 20892, United StatesJulia S Yarrington - Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Building 10, CRC Room 7-5341, 10 Center Drive, MSC 1282, Bethesda, MD 20892, United StatesCristan A Farmer - Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Building 10, CRC Room 7-5341, 10 Center Drive, MSC 1282, Bethesda, MD 20892, United StatesErica Richards - Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Building 10, CRC Room 7-5341, 10 Center Drive, MSC 1282, Bethesda, MD 20892, United StatesRodrigo Machado-Vieira - Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Building 10, CRC Room 7-5341, 10 Center Drive, MSC 1282, Bethesda, MD 20892, United StatesBashkim Kadriu - Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Building 10, CRC Room 7-5341, 10 Center Drive, MSC 1282, Bethesda, MD 20892, United StatesMark J Niciu - Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Building 10, CRC Room 7-5341, 10 Center Drive, MSC 1282, Bethesda, MD 20892, United StatesPeixiong Yuan - Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Building 10, CRC Room 7-5341, 10 Center Drive, MSC 1282, Bethesda, MD 20892, United StatesLawrence Park - Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Building 10, CRC Room 7-5341, 10 Center Drive, MSC 1282, Bethesda, MD 20892, United StatesCarlos A Zarate - Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Building 10, CRC Room 7-5341, 10 Center Drive, MSC 1282, Bethesda, MD 20892, United States
- Resource Type
- Journal article
- Publication Details
- Journal of affective disorders, Vol.241, pp.86-93
- DOI
- 10.1016/j.jad.2018.07.077
- PMID
- 30099268
- PMCID
- PMC6193483
- NLM abbreviation
- J Affect Disord
- ISSN
- 0165-0327
- eISSN
- 1573-2517
- Publisher
- Elsevier B.V
- Language
- English
- Date published
- 12/01/2018
- Academic Unit
- Psychiatry; Iowa Neuroscience Institute
- Record Identifier
- 9984070439202771
Metrics
13 Record Views